Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data.

The results show that the core candidate drug Annamycin demonstrated significantly superior efficacy in inducing complete remission compared to the control group, with the complete remission rate reaching three times that of the control group. This positive data provides strong momentum for the further development of Annamycin in the treatment of acute myeloid leukemia. The success of the interim analysis indicates that the drug has made breakthrough progress in key efficacy indicators, and it is expected to offer new treatment options for patients. The company will continue to advance clinical trials to obtain more confirmatory data.